APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Research

Biosimilars Industry Research Report 2026

22 December 2025146 pages

Choose your research edition.

Industry ResearchBiosimilars Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Biosimilars is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Biosimilars is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Biosimilars include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Biosimilars market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Biosimilars Market by Company

Teva Pharmaceutical

Samsung Biologics

Novartis

Merck KgaA

Mylan

Roche

Eli Lilly

Pfizer

Gan & Lee Pharmaceuticals

Biogen

Amgen

Stada Arzneimittel AG

Probiomed

JCR Pharmaceuticals

Gedeon Richter

Fresenius Kabi AG

Dr. Reddy's Laboratories

Coherus Bioscience

Chong Kun Dang

Celltrion

Boehringer Ingelheim

Biocon

Biocad

Apotex

Biosimilars Segment by Type

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

Recombinant Glycosylated Proteins

Biosimilars Segment by Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Chronic and Autoimmune Disorders

Others

Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Biosimilars Sales (k units) of Manufacturers (2021-2026) Table 7. Global Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 8. Global Biosimilars Revenue of Manufacturers (2021-2026) Table 9. Global Biosimilars Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Biosimilars Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Biosimilars Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Biosimilars, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Biosimilars, Product Type & Application Table 14. Global Biosimilars Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Company Information Table 19. Teva Pharmaceutical Business Overview Table 20. Teva Pharmaceutical Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Biosimilars Product Portfolio Table 22. Teva Pharmaceutical Recent Developments Table 23. Samsung Biologics Company Information Table 24. Samsung Biologics Business Overview Table 25. Samsung Biologics Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Samsung Biologics Biosimilars Product Portfolio Table 27. Samsung Biologics Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Novartis Biosimilars Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck KgaA Company Information Table 34. Merck KgaA Business Overview Table 35. Merck KgaA Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Merck KgaA Biosimilars Product Portfolio Table 37. Merck KgaA Recent Developments Table 38. Mylan Company Information Table 39. Mylan Business Overview Table 40. Mylan Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Mylan Biosimilars Product Portfolio Table 42. Mylan Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Roche Biosimilars Product Portfolio Table 47. Roche Recent Developments Table 48. Eli Lilly Company Information Table 49. Eli Lilly Business Overview Table 50. Eli Lilly Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Eli Lilly Biosimilars Product Portfolio Table 52. Eli Lilly Recent Developments Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Pfizer Biosimilars Product Portfolio Table 57. Pfizer Recent Developments Table 58. Gan & Lee Pharmaceuticals Company Information Table 59. Gan & Lee Pharmaceuticals Business Overview Table 60. Gan & Lee Pharmaceuticals Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Gan & Lee Pharmaceuticals Biosimilars Product Portfolio Table 62. Gan & Lee Pharmaceuticals Recent Developments Table 63. Biogen Company Information Table 64. Biogen Business Overview Table 65. Biogen Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Biogen Biosimilars Product Portfolio Table 67. Biogen Recent Developments Table 68. Amgen Company Information Table 69. Amgen Business Overview Table 70. Amgen Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Amgen Biosimilars Product Portfolio Table 72. Amgen Recent Developments Table 73. Stada Arzneimittel AG Company Information Table 74. Stada Arzneimittel AG Business Overview Table 75. Stada Arzneimittel AG Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Stada Arzneimittel AG Biosimilars Product Portfolio Table 77. Stada Arzneimittel AG Recent Developments Table 78. Probiomed Company Information Table 79. Probiomed Business Overview Table 80. Probiomed Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Probiomed Biosimilars Product Portfolio Table 82. Probiomed Recent Developments Table 83. JCR Pharmaceuticals Company Information Table 84. JCR Pharmaceuticals Business Overview Table 85. JCR Pharmaceuticals Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. JCR Pharmaceuticals Biosimilars Product Portfolio Table 87. JCR Pharmaceuticals Recent Developments Table 88. Gedeon Richter Company Information Table 89. Gedeon Richter Business Overview Table 90. Gedeon Richter Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Gedeon Richter Biosimilars Product Portfolio Table 92. Gedeon Richter Recent Developments Table 93. Fresenius Kabi AG Company Information Table 94. Fresenius Kabi AG Business Overview Table 95. Fresenius Kabi AG Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Fresenius Kabi AG Biosimilars Product Portfolio Table 97. Fresenius Kabi AG Recent Developments Table 98. Dr. Reddy's Laboratories Company Information Table 99. Dr. Reddy's Laboratories Business Overview Table 100. Dr. Reddy's Laboratories Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Dr. Reddy's Laboratories Biosimilars Product Portfolio Table 102. Dr. Reddy's Laboratories Recent Developments Table 103. Coherus Bioscience Company Information Table 104. Coherus Bioscience Business Overview Table 105. Coherus Bioscience Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Coherus Bioscience Biosimilars Product Portfolio Table 107. Coherus Bioscience Recent Developments Table 108. Chong Kun Dang Company Information Table 109. Chong Kun Dang Business Overview Table 110. Chong Kun Dang Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Chong Kun Dang Biosimilars Product Portfolio Table 112. Chong Kun Dang Recent Developments Table 113. Celltrion Company Information Table 114. Celltrion Business Overview Table 115. Celltrion Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Celltrion Biosimilars Product Portfolio Table 117. Celltrion Recent Developments Table 118. Boehringer Ingelheim Company Information Table 119. Boehringer Ingelheim Business Overview Table 120. Boehringer Ingelheim Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Boehringer Ingelheim Biosimilars Product Portfolio Table 122. Boehringer Ingelheim Recent Developments Table 123. Biocon Company Information Table 124. Biocon Business Overview Table 125. Biocon Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Biocon Biosimilars Product Portfolio Table 127. Biocon Recent Developments Table 128. Biocad Company Information Table 129. Biocad Business Overview Table 130. Biocad Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Biocad Biosimilars Product Portfolio Table 132. Biocad Recent Developments Table 133. Apotex Company Information Table 134. Apotex Business Overview Table 135. Apotex Biosimilars Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Apotex Biosimilars Product Portfolio Table 137. Apotex Recent Developments Table 138. Global Biosimilars Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 139. Global Biosimilars Sales by Region (2021-2026) & (k units) Table 140. Global Biosimilars Sales Market Share by Region (2021-2026) Table 141. Global Biosimilars Sales by Region (2027-2032) & (k units) Table 142. Global Biosimilars Sales Market Share by Region (2027-2032) Table 143. Global Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 144. Global Biosimilars Revenue Market Share by Region (2021-2026) Table 145. Global Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 146. Global Biosimilars Revenue Market Share by Region (2027-2032) Table 147. North America Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. North America Biosimilars Sales by Country (2021-2026) & (k units) Table 149. North America Biosimilars Sales by Country (2027-2032) & (k units) Table 150. North America Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 152. Europe Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Europe Biosimilars Sales by Country (2021-2026) & (k units) Table 154. Europe Biosimilars Sales by Country (2027-2032) & (k units) Table 155. Europe Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 156. Europe Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 157. Asia Pacific Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Asia Pacific Biosimilars Sales by Country (2021-2026) & (k units) Table 159. Asia Pacific Biosimilars Sales by Country (2027-2032) & (k units) Table 160. Asia Pacific Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 161. Asia Pacific Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 162. South America Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. South America Biosimilars Sales by Country (2021-2026) & (k units) Table 164. South America Biosimilars Sales by Country (2027-2032) & (k units) Table 165. South America Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 166. South America Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Middle East and Africa Biosimilars Sales by Country (2021-2026) & (k units) Table 169. Middle East and Africa Biosimilars Sales by Country (2027-2032) & (k units) Table 170. Middle East and Africa Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 172. Global Biosimilars Sales by Type (2021-2026) & (k units) Table 173. Global Biosimilars Sales by Type (2027-2032) & (k units) Table 174. Global Biosimilars Sales Market Share by Type (2021-2026) Table 175. Global Biosimilars Sales Market Share by Type (2027-2032) Table 176. Global Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 177. Global Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 178. Global Biosimilars Revenue Market Share by Type (2021-2026) Table 179. Global Biosimilars Revenue Market Share by Type (2027-2032) Table 180. Global Biosimilars Price by Type (2021-2026) & (US$/unit) Table 181. Global Biosimilars Price by Type (2027-2032) & (US$/unit) Table 182. Global Biosimilars Sales by Application (2021-2026) & (k units) Table 183. Global Biosimilars Sales by Application (2027-2032) & (k units) Table 184. Global Biosimilars Sales Market Share by Application (2021-2026) Table 185. Global Biosimilars Sales Market Share by Application (2027-2032) Table 186. Global Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 187. Global Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 188. Global Biosimilars Revenue Market Share by Application (2021-2026) Table 189. Global Biosimilars Revenue Market Share by Application (2027-2032) Table 190. Global Biosimilars Price by Application (2021-2026) & (US$/unit) Table 191. Global Biosimilars Price by Application (2027-2032) & (US$/unit) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Biosimilars Distributors List Table 195. Biosimilars Customers List Table 196. Biosimilars Industry Trends Table 197. Biosimilars Industry Drivers Table 198. Biosimilars Industry Restraints Table 199. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Biosimilars Product Image Figure 5. Global Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Biosimilars Market Size (2021-2032) & (US$ Million) Figure 7. Global Biosimilars Sales (2021-2032) & (k units) Figure 8. Global Biosimilars Average Price (US$/unit) & (2021-2032) Figure 9. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Product Image Figure 10. Recombinant Glycosylated Proteins Product Image Figure 11. Oncology Product Image Figure 12. Blood Disorders Product Image Figure 13. Growth Hormonal Deficiency Product Image Figure 14. Chronic and Autoimmune Disorders Product Image Figure 15. Others Product Image Figure 16. Global Biosimilars Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Biosimilars, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Biosimilars Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Biosimilars Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Biosimilars Sales by Region in 2025 Figure 22. Global Biosimilars Revenue by Region in 2025 Figure 23. North America Biosimilars Market Size by Country in 2025 Figure 24. North America Biosimilars Sales Market Share by Country (2021-2032) Figure 25. North America Biosimilars Revenue Market Share by Country (2021-2032) Figure 26. United States Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Biosimilars Market Size by Country in 2025 Figure 30. Europe Biosimilars Sales Market Share by Country (2021-2032) Figure 31. Europe Biosimilars Revenue Market Share by Country (2021-2032) Figure 32. Germany Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Biosimilars Market Size by Country in 2025 Figure 43. Asia Pacific Biosimilars Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Biosimilars Revenue Market Share by Country (2021-2032) Figure 45. China Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Biosimilars Market Size by Country in 2025 Figure 54. South America Biosimilars Sales Market Share by Country (2021-2032) Figure 55. South America Biosimilars Revenue Market Share by Country (2021-2032) Figure 56. Brazil Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Colombia Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Biosimilars Market Size by Country in 2025 Figure 61. Middle East and Africa Biosimilars Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Biosimilars Revenue Market Share by Country (2021-2032) Figure 63. Egypt Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Biosimilars Sales Market Share by Type (2021-2032) Figure 69. Global Biosimilars Revenue Market Share by Type (2021-2032) Figure 70. Global Biosimilars Price (US$/unit) by Type (2021-2032) Figure 71. Global Biosimilars Sales Market Share by Application (2021-2032) Figure 72. Global Biosimilars Revenue Market Share by Application (2021-2032) Figure 73. Global Biosimilars Price (US$/unit) by Application (2021-2032) Figure 74. Biosimilars Value Chain Figure 75. Biosimilars Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Biosimilars Industry Opportunities and Challenges

Scope & coverage.

Types
  • Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  • Recombinant Glycosylated Proteins
Applications
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others
Companies covered
  • Teva Pharmaceutical
  • Samsung Biologics
  • Novartis
  • Merck KgaA
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Gan & Lee Pharmaceuticals
  • Biogen
  • Amgen
  • Stada Arzneimittel AG
  • Probiomed
  • JCR Pharmaceuticals
  • Gedeon Richter
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories
  • Coherus Bioscience
  • Chong Kun Dang
  • Celltrion
  • Boehringer Ingelheim
  • Biocon
  • Biocad
  • Apotex

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Biosimilars Market Size (2021-2032)
  4. 2.2.2 Global Biosimilars Sales (2021-2032)
  5. 2.2.3 Global Biosimilars Market Average Price (2021-2032)
  6. 2.3 Biosimilars by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  9. 2.3.3 Recombinant Glycosylated Proteins
  10. 2.4 Biosimilars by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Oncology
  13. 2.4.3 Blood Disorders
  14. 2.4.4 Growth Hormonal Deficiency
  15. 2.4.5 Chronic and Autoimmune Disorders
  16. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Biosimilars Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Biosimilars Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Biosimilars Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Biosimilars Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Biosimilars Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Biosimilars, Product Type & Application
  8. 3.8 Global Manufacturers of Biosimilars, Established Date
  9. 3.9 Global Biosimilars Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical
  2. 4.1.1 Teva Pharmaceutical Company Information
  3. 4.1.2 Teva Pharmaceutical Business Overview
  4. 4.1.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Recent Developments
  7. 4.2 Samsung Biologics
  8. 4.2.1 Samsung Biologics Company Information
  9. 4.2.2 Samsung Biologics Business Overview
  10. 4.2.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Samsung Biologics Biosimilars Product Portfolio
  12. 4.2.5 Samsung Biologics Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Biosimilars Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck KgaA
  20. 4.4.1 Merck KgaA Company Information
  21. 4.4.2 Merck KgaA Business Overview
  22. 4.4.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck KgaA Biosimilars Product Portfolio
  24. 4.4.5 Merck KgaA Recent Developments
  25. 4.5 Mylan
  26. 4.5.1 Mylan Company Information
  27. 4.5.2 Mylan Business Overview
  28. 4.5.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan Biosimilars Product Portfolio
  30. 4.5.5 Mylan Recent Developments
  31. 4.6 Roche
  32. 4.6.1 Roche Company Information
  33. 4.6.2 Roche Business Overview
  34. 4.6.3 Roche Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Roche Biosimilars Product Portfolio
  36. 4.6.5 Roche Recent Developments
  37. 4.7 Eli Lilly
  38. 4.7.1 Eli Lilly Company Information
  39. 4.7.2 Eli Lilly Business Overview
  40. 4.7.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Eli Lilly Biosimilars Product Portfolio
  42. 4.7.5 Eli Lilly Recent Developments
  43. 4.8 Pfizer
  44. 4.8.1 Pfizer Company Information
  45. 4.8.2 Pfizer Business Overview
  46. 4.8.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pfizer Biosimilars Product Portfolio
  48. 4.8.5 Pfizer Recent Developments
  49. 4.9 Gan & Lee Pharmaceuticals
  50. 4.9.1 Gan & Lee Pharmaceuticals Company Information
  51. 4.9.2 Gan & Lee Pharmaceuticals Business Overview
  52. 4.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
  54. 4.9.5 Gan & Lee Pharmaceuticals Recent Developments
  55. 4.10 Biogen
  56. 4.10.1 Biogen Company Information
  57. 4.10.2 Biogen Business Overview
  58. 4.10.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Biogen Biosimilars Product Portfolio
  60. 4.10.5 Biogen Recent Developments
  61. 4.11 Amgen
  62. 4.11.1 Amgen Company Information
  63. 4.11.2 Amgen Business Overview
  64. 4.11.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Amgen Biosimilars Product Portfolio
  66. 4.11.5 Amgen Recent Developments
  67. 4.12 Stada Arzneimittel AG
  68. 4.12.1 Stada Arzneimittel AG Company Information
  69. 4.12.2 Stada Arzneimittel AG Business Overview
  70. 4.12.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
  72. 4.12.5 Stada Arzneimittel AG Recent Developments
  73. 4.13 Probiomed
  74. 4.13.1 Probiomed Company Information
  75. 4.13.2 Probiomed Business Overview
  76. 4.13.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Probiomed Biosimilars Product Portfolio
  78. 4.13.5 Probiomed Recent Developments
  79. 4.14 JCR Pharmaceuticals
  80. 4.14.1 JCR Pharmaceuticals Company Information
  81. 4.14.2 JCR Pharmaceuticals Business Overview
  82. 4.14.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
  84. 4.14.5 JCR Pharmaceuticals Recent Developments
  85. 4.15 Gedeon Richter
  86. 4.15.1 Gedeon Richter Company Information
  87. 4.15.2 Gedeon Richter Business Overview
  88. 4.15.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Gedeon Richter Biosimilars Product Portfolio
  90. 4.15.5 Gedeon Richter Recent Developments
  91. 4.16 Fresenius Kabi AG
  92. 4.16.1 Fresenius Kabi AG Company Information
  93. 4.16.2 Fresenius Kabi AG Business Overview
  94. 4.16.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
  96. 4.16.5 Fresenius Kabi AG Recent Developments
  97. 4.17 Dr. Reddy's Laboratories
  98. 4.17.1 Dr. Reddy's Laboratories Company Information
  99. 4.17.2 Dr. Reddy's Laboratories Business Overview
  100. 4.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
  102. 4.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 4.18 Coherus Bioscience
  104. 4.18.1 Coherus Bioscience Company Information
  105. 4.18.2 Coherus Bioscience Business Overview
  106. 4.18.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Coherus Bioscience Biosimilars Product Portfolio
  108. 4.18.5 Coherus Bioscience Recent Developments
  109. 4.19 Chong Kun Dang
  110. 4.19.1 Chong Kun Dang Company Information
  111. 4.19.2 Chong Kun Dang Business Overview
  112. 4.19.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Chong Kun Dang Biosimilars Product Portfolio
  114. 4.19.5 Chong Kun Dang Recent Developments
  115. 4.20 Celltrion
  116. 4.20.1 Celltrion Company Information
  117. 4.20.2 Celltrion Business Overview
  118. 4.20.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Celltrion Biosimilars Product Portfolio
  120. 4.20.5 Celltrion Recent Developments
  121. 4.21 Boehringer Ingelheim
  122. 4.21.1 Boehringer Ingelheim Company Information
  123. 4.21.2 Boehringer Ingelheim Business Overview
  124. 4.21.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
  126. 4.21.5 Boehringer Ingelheim Recent Developments
  127. 4.22 Biocon
  128. 4.22.1 Biocon Company Information
  129. 4.22.2 Biocon Business Overview
  130. 4.22.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Biocon Biosimilars Product Portfolio
  132. 4.22.5 Biocon Recent Developments
  133. 4.23 Biocad
  134. 4.23.1 Biocad Company Information
  135. 4.23.2 Biocad Business Overview
  136. 4.23.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Biocad Biosimilars Product Portfolio
  138. 4.23.5 Biocad Recent Developments
  139. 4.24 Apotex
  140. 4.24.1 Apotex Company Information
  141. 4.24.2 Apotex Business Overview
  142. 4.24.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Apotex Biosimilars Product Portfolio
  144. 4.24.5 Apotex Recent Developments
5 Global Biosimilars Market Scenario by Region
  1. 5.1 Global Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Biosimilars Sales by Region: 2021-2032
  3. 5.2.1 Global Biosimilars Sales by Region: 2021-2026
  4. 5.2.2 Global Biosimilars Sales by Region: 2027-2032
  5. 5.3 Global Biosimilars Revenue by Region: 2021-2032
  6. 5.3.1 Global Biosimilars Revenue by Region: 2021-2026
  7. 5.3.2 Global Biosimilars Revenue by Region: 2027-2032
  8. 5.4 North America Biosimilars Market Facts & Figures by Country
  9. 5.4.1 North America Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Biosimilars Sales by Country (2021-2032)
  11. 5.4.3 North America Biosimilars Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Biosimilars Market Facts & Figures by Country
  16. 5.5.1 Europe Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Biosimilars Sales by Country (2021-2032)
  18. 5.5.3 Europe Biosimilars Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Biosimilars Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Biosimilars Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Biosimilars Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Biosimilars Market Facts & Figures by Country
  41. 5.7.1 South America Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Biosimilars Sales by Country (2021-2032)
  43. 5.7.3 South America Biosimilars Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Biosimilars Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Biosimilars Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Biosimilars Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Biosimilars Sales by Type (2021-2032)
  2. 6.1.1 Global Biosimilars Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Biosimilars Sales Market Share by Type (2021-2032)
  4. 6.2 Global Biosimilars Revenue by Type (2021-2032)
  5. 6.2.1 Global Biosimilars Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Biosimilars Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Biosimilars Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Biosimilars Sales by Application (2021-2032)
  2. 7.1.1 Global Biosimilars Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Biosimilars Sales Market Share by Application (2021-2032)
  4. 7.2 Global Biosimilars Revenue by Application (2021-2032)
  5. 7.2.1 Global Biosimilars Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Biosimilars Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Biosimilars Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Biosimilars Value Chain Analysis
  2. 8.1.1 Biosimilars Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Biosimilars Production Mode & Process
  5. 8.2 Biosimilars Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Biosimilars Distributors
  8. 8.2.3 Biosimilars Customers
9 Global Biosimilars Analyzing Market Dynamics
  1. 9.1 Biosimilars Industry Trends
  2. 9.2 Biosimilars Industry Drivers
  3. 9.3 Biosimilars Industry Opportunities and Challenges
  4. 9.4 Biosimilars Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst